VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
The Phase I study demonstrated a clear dose-response relationship between the amount of rPA102 administered and the subsequent immune response, with antibody titers continuing to increase after the second and third administration. The vaccine was well-tolerated, with no evidence of dose-limiting toxicity or reactogenicity at any dose.